Nefopam Chlorhydrate Eg Labo (Nefopam Hydrochloride)

Nefopam Hydrochloride is used to treat pain conditions that involve central pain pathways.

• Moderate acute pain: provides analgesia for sudden, short‑term pain episodes such as injury or trauma.
• Post‑operative pain: helps control pain following surgical procedures.
• Pain after major trauma: reduces discomfort associated with severe tissue injury.

• Nefopam inhibits the reuptake of norepinephrine, serotonin and dopamine in the central nervous system, thereby enhancing descending inhibitory pain pathways. This multimodal neurotransmitter modulation reduces the perception of pain without acting on opioid receptors, offering analgesia while avoiding typical opioid‑related effects.

Nefopam may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

• Nausea: mild to moderate upset stomach.
• Sweating: increased perspiration without exertion.
• Dry mouth: reduced salivation.
• Dizziness: light‑headed sensation.
• Tachycardia: faster than normal heart rate.
• Blurred vision: temporary visual disturbance.

Serious or Rare Side Effects

• Seizures: convulsive episodes, especially in predisposed individuals.
• Severe hypotension: marked drop in blood pressure.
• Allergic reactions: rash, itching, or anaphylaxis.
• Cardiac arrhythmia: irregular heart rhythm.
• Hepatic dysfunction: abnormal liver enzyme elevations.
• Neuropsychiatric effects: agitation or confusion.

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor for adverse events.

• Cardiovascular assessment: check blood pressure and heart rate before use.
• Seizure risk: avoid in patients with a history of epilepsy.
• Hepatic/renal function: adjust use if liver or kidney impairment is present.
• Glaucoma caution: monitor intra‑ocular pressure in susceptible patients.
• Discontinuation: taper gradually to prevent withdrawal phenomena.
• Store below 25°C: keep in the original container, protect from light and moisture.

Nefopam can interact with several drug classes; awareness of these interactions helps prevent adverse outcomes.

Major Interactions (Avoid)

• Monoamine oxidase inhibitors (MAOIs): risk of severe hypertension or serotonin syndrome.
• Selective serotonin reuptake inhibitors (SSRIs): increased serotonin toxicity.
• Tricyclic antidepressants: heightened seizure risk.
• Antihypertensive agents: additive hypotensive effect.

Moderate Interactions (Monitor Closely)

• CYP450 inhibitors (e.g., fluoxetine): may raise nefopam plasma levels.
• CYP450 inducers (e.g., carbamazepine): may reduce efficacy.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs): combined gastrointestinal irritation.
• Anticholinergic drugs: may exacerbate dry mouth.
• Diuretics: potential electrolyte disturbances.